Standout Papers

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02)... 2013 2026 2017 2021 398
  1. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial (2013)
    Hugo Ford, Andrea Marshall et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 62 standout
Sub-graph 1 of 18

Citing Papers

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
2022 Standout
Aptamer-Based Detection of Circulating Targets for Precision Medicine
2021 Standout
5 intermediate papers

Works of Hugo Ford being referenced

The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer
2004
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
2003
and 1 more

Author Peers

Author Last Decade Papers Cites
Hugo Ford 760 710 325 32 1.1k
Eunmi Nam 643 504 286 30 1.1k
Akito Matsukuma 527 563 451 33 1.2k
Cun Liao 336 359 191 41 1.0k
Francesca Di Fabio 731 782 412 63 1.3k
Sohei Matsumoto 580 631 579 63 1.2k
Maria Ignez Braghiroli 296 570 224 57 877
Antonia Strippoli 422 516 318 65 1.0k
Kohei Wakatsuki 502 529 494 56 1.1k
Ricardo Cubedo 619 551 216 48 1.1k
Stephan Hollerbach 764 632 760 46 1.3k

All Works

Loading papers...

Rankless by CCL
2026